GSK invests £1 billion against infectious diseases in low-income countries

Belgian based Pharma company GSK will invest 1 billion pounds (some 1.165 billion euros) in research and development over 10 years to stay one step ahead of infectious diseases in low-income countries. The compagnie sets itself the ambition of making a positive impact on the health of more than 2.5 billion people over the next decade.

The new investments are intended to accelerate research and development on infectious diseases that disproportionately impact lower-income countries. The research is focused on new and disruptive vaccines and drugs to prevent and cure infectious diseases. These include malaria, tuberculosis, HIV, neglected tropical diseases and antimicrobial resistance. Those diseases represent more than 60 percent of the disease burden in many low-income countries, according to GSK.

The pharma company says it set up specific, non-commercial units whose success is measured only by health impact. "The model is designed to prioritize the prevention and treatment of infectious diseases in low-income countries, where the company's science can impact the health of millions in disease areas with little prospect of a commercial return on investment," GSK said.

The pharma company says it is working on more than 30 potential new vaccines and drugs, against 13 infectious diseases "that particularly affect many people."

Thomas Breuer, GSK's director of global health, made the announcement at a summit in Kigali on malaria and neglected tropical diseases. The pharma company also announced there to supply albendazole until lymphatic filariasis is eradicated and to double production of the adjuvant to the malaria vaccine RTS,S.



© BELGA PHOTO Kenzo TRIBOUILLARD - A GSK employee is at work at the factory of British pharmaceutical company GlaxoSmithKline (GSK) in Wavre on February 8, 2021 where the Covid-19 CureVac vaccine will be produced.

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.


Belga News Agency delivers dependable, rapid and high-quality information 24 hours a day, 7 days a week, from Belgium and abroad to all Belgian media. The information covers all sectors, from politics, economics and finance to social affairs, sports and culture, not to mention entertainment and lifestyle.

Every day, our journalists and press photographers produce hundreds of photos and news stories, dozens of online information items, plus audio and video bulletins, all in both national languages. Since the end of March 2022 English has been added as a language.

For public institutions, businesses and various organisations that need reliable information, Belga News Agency also offers a comprehensive range of corporate services to meet all their communication needs.


Arduinkaai 29 1000 Brussels